Charles Schwab Investment Management Inc. Buys 163,160 Shares of Renovaro Inc. (NASDAQ:RENB)

Charles Schwab Investment Management Inc. increased its stake in Renovaro Inc. (NASDAQ:RENB) by 82.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 362,126 shares of the company’s stock after purchasing an additional 163,160 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.23% of Renovaro worth $303,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Bank of New York Mellon Corp grew its stake in Renovaro by 137.2% during the fourth quarter. Bank of New York Mellon Corp now owns 223,915 shares of the company’s stock valued at $187,000 after acquiring an additional 129,529 shares in the last quarter. Rhumbline Advisers boosted its holdings in Renovaro by 122.6% in the 4th quarter. Rhumbline Advisers now owns 112,960 shares of the company’s stock valued at $94,000 after purchasing an additional 62,204 shares during the period. SG Americas Securities LLC grew its position in shares of Renovaro by 193.3% during the 4th quarter. SG Americas Securities LLC now owns 51,725 shares of the company’s stock valued at $43,000 after purchasing an additional 34,090 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Renovaro by 347.6% in the third quarter. JPMorgan Chase & Co. now owns 93,010 shares of the company’s stock worth $45,000 after purchasing an additional 72,230 shares during the period. Finally, Barclays PLC raised its position in shares of Renovaro by 315.7% in the third quarter. Barclays PLC now owns 69,531 shares of the company’s stock worth $34,000 after buying an additional 52,804 shares in the last quarter. 71.41% of the stock is currently owned by institutional investors.

Renovaro Trading Down 7.8 %

Shares of RENB opened at $0.50 on Wednesday. Renovaro Inc. has a 12-month low of $0.40 and a 12-month high of $3.00. The company has a market cap of $79.45 million, a PE ratio of -0.54 and a beta of 0.42. The stock has a 50-day moving average price of $0.79 and a 200-day moving average price of $0.79.

Renovaro (NASDAQ:RENB) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($0.02) earnings per share for the quarter.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.